

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

Claims 1-6 (Canceled)

Claim 7. (Previously presented) A method of evaluating the effectiveness of an antiviral therapy of an HIV infected patient comprising:

(i) collecting a sample from an HIV-infected patient;

(ii) determining in said sample each of the following nucleic acids:

(a) a first nucleic acid encoding HIV reverse transcriptase comprising at least one mutation chosen from:

1) 88E, 101H, 101N, 101P, 101Q, 101T, 103H, 103S, 179I, 179E, 181V, 190E, 190S, or 190T,

2) mutations 103 R and 179D, or

3) combinations of 1) and 2),

in which the presence of said at least one mutation correlates with resistance to at least one Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI);

(b) a second nucleic acid encoding HIV reverse transcriptase comprising at least one mutation chosen from 69S-[S-S], 184G, 184L, 215V, 44D, 44A, and 118I,

in which the presence of said at least one mutation correlates with resistance to at least one Nucleoside Reverse Transcriptase Inhibitor (NRTI); and

(c) a third nucleic acid encoding HIV protease [having] comprising at least one mutation chosen from:

1) 88T, or

2) mutations 33F and 90M, or

3) combinations of 1) and 2),

in which the presence of said at least one mutation correlates with resistance to at least one Protease Inhibitor (PI); and

(d) wherein the antiviral therapy includes nucleoside reverse transcriptase inhibitors (NRTIs) which are one or more drugs of the group selected from zidovudine (ZDV), didanosine (ddl), zalcitabine (ddC), stavudine (d4T), lamivudine (3TC) and abacavir

**DOCKET NO.:** TIBO-0016/VIP0004USA  
**Application No.:** 09/580,491  
**Office Action Dated:** December 16, 2004

**PATENT**

(ABC); non-nucleoside reverse transcriptase inhibitors (NNRTIs) which are one or more drugs of the group selected from nevirapine (NVP), delavirdine (DLV) and efavirenz; and protease inhibitors (PIs) which are one or more drugs of the group selected from saquinavir (SQV), ritonavir (RTV), indinavir (IDV) nelfinavir (NFV), amprenavir (APV) and ABT-378.

Claims 8-30 (Canceled)